Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton; Harold A. Harvey; Bellarmine Lawrence; Robert Gottlieb; Miodrag Kukrika; Richard Dixon; William Graham; Stephen Miller; Robert Heckard; Dale Schelzel; Deborah S. White

doi:10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton
, Harold A. Harvey
, Bellarmine Lawrence
, Robert Gottlieb
, Miodrag Kukrika
, Richard Dixon
, William Graham
, Stephen Miller
, Robert Heckard
, Dale Schelzel
, Deborah S. White

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

Original language	English (US)
Pages (from-to)	57-60
Number of pages	4
Journal	Cancer
Volume	51
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V
State	Published - Jan 1 1983

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

Cite this

@article{5d4ccfab54c548af902dea239fceb5b9,

title = "Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma",

abstract = "One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.",

author = "Allan Lipton and Harvey, \{Harold A.\} and Bellarmine Lawrence and Robert Gottlieb and Miodrag Kukrika and Richard Dixon and William Graham and Stephen Miller and Robert Heckard and Dale Schelzel and White, \{Deborah S.\}",

year = "1983",

month = jan,

day = "1",

doi = "10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V",

language = "English (US)",

volume = "51",

pages = "57--60",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

AU - Lipton, Allan

AU - Harvey, Harold A.

AU - Lawrence, Bellarmine

AU - Gottlieb, Robert

AU - Kukrika, Miodrag

AU - Dixon, Richard

AU - Graham, William

AU - Miller, Stephen

AU - Heckard, Robert

AU - Schelzel, Dale

AU - White, Deborah S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

AB - One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

UR - https://www.scopus.com/pages/publications/0020659801

UR - https://www.scopus.com/pages/publications/0020659801#tab=citedBy

U2 - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

DO - 10.1002/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V

M3 - Article

C2 - 6821809

AN - SCOPUS:0020659801

SN - 0008-543X

VL - 51

SP - 57

EP - 60

JO - Cancer

JF - Cancer

IS - 1

ER -

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this